Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of chrysin in preparation of medicines for treating cerebral arterial thrombosis

A technology for ischemic stroke and chrysin, which is applied in the directions of drug combinations, medical preparations containing active ingredients, and pharmaceutical formulas, which can solve the problem of unreported therapeutic effects.

Inactive Publication Date: 2013-11-27
GENERAL HOSPITAL OF TIANJIN MEDICAL UNIV
View PDF4 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The existing technology shows that chrysin has various biological properties such as anti-tumor and anti-inflammation, but so far there is no report on the therapeutic effect of chrysin on ischemic stroke

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of chrysin in preparation of medicines for treating cerebral arterial thrombosis
  • Application of chrysin in preparation of medicines for treating cerebral arterial thrombosis
  • Application of chrysin in preparation of medicines for treating cerebral arterial thrombosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] 1.1 Establishment of MCAO mouse model

[0022] (1) Experimental animals and sources

[0023] Seventy-two male wild-type C57 / BL6 pathogen-free (SPF grade) mice, 6-8 weeks old, weighing 25-30g, were purchased from the Experimental Animal Center of the Academy of Military Medical Sciences of the Chinese People's Liberation Army, and were raised with the Experimental Animal Center of Tianjin Medical University, small Rats are kept in a room temperature of 20-25°C and a relative humidity of 40%-60%.

[0024] (2) Experimental grouping

[0025] In order to study the drug effect of chrysin in the mouse MCAO animal model, the mice were randomly divided into three groups, 24 in each group, respectively sham operation group; ischemia-reperfusion model group (model group); chrysin treatment group ( therapy group). Chrysin 50 mg / Kg / day was administered orally to the treatment group and 7 days before the preparation of the MCAO model. The sham operation group and the model group ...

Embodiment 2

[0201] Mix 50g of chrysin and 280g of starch evenly, make granules with starch slurry (take 220g of starch and make starch slurry with water), sieve, dry, and pack into capsules.

Embodiment 3

[0203] Mix 80g of chrysin and 340g of starch evenly, make granules with starch slurry (take 210g of starch to make starch slurry with water), sieve, dry, add 6% magnesium stearate, mix evenly, press into tablets, and coat with film. .

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Melting pointaaaaaaaaaa
Melting pointaaaaaaaaaa
Login to View More

Abstract

The invention discloses an application of chrysin in the preparation of medicines for treating cerebral arterial thrombosis. Experimental results of the chrysin show that the chrysin has a relatively good nerve protection effect on focal cerebral ischemia-reperfusion injury, can be used for improving the neurological function loss after the cerebral ischemia-reperfusion injury, reducing the water content in brains, the size of cerebral infarction and the content of malonaldehyde (MDA) and improving the activity of superoxide dismutase (SOD); after focal cerebral ischemia-reperfusion, the chrysin can be used for reducing the relative expression quantity of nuclear factor-kappaB (NF-kappaB) of ischemia-reperfusion brain tissues, inducible nitric oxide synthase (iNOS) and a cyclooxygenase-2 (COX-2) gene; and the chrysin can also be used for reducing the expression of GFAP and Iba1 in the ischemia-reperfusion brain tissues, inhibiting the activation of astrocyte and microglial cells and meanwhile reducing the expression of pro-inflammatory cytokines such as IL-1alpha, IL-1beta, IL-6, IL-12, IL-17A, TNF-alpha and IFN-gamma, thus the excessive inflammatory response of cerebral ischemia tissues is alleviated, and the neuroprotective effect after ischemia is realized.

Description

technical field [0001] The invention relates to a new application of the compound chrysin, in particular to the application of chrysin in the preparation of medicine for treating ischemic stroke. Background technique [0002] Cerebrovascular disease is one of the three major diseases that cause human death. Its high mortality and disability rate have brought heavy burdens to society and families. As one of the most serious symptoms among cerebrovascular diseases, ischemic stroke is extremely harmful to the health of patients and often causes irreversible brain damage. Due to the interruption of cerebral arterial blood flow and oxygen supply, the physiological activity of the brain is significantly damaged, which leads to a series of complex pathophysiological processes, including brain tissue energy metabolism disorder, excitatory amino acid toxicity, free radical damage, inflammatory response, apoptosis, etc. death and so on. After cerebral ischemia restores the blood sup...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/352A61P9/10A61P25/00
Inventor 郝峻巍么阳肖金婷
Owner GENERAL HOSPITAL OF TIANJIN MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com